October 31, 2008
Bayhill Therapeutics and JDRF Partner in Diabetes Drug Development
Bayhill Therapeutics, a biopharmaceutical company, and the Juvenile Diabetes Research Foundation have announced a partnership to support Bayhill's ongoing Phase I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes Type 1 diabetes.
The agreement with Bayhill is a part of Juvenile Diabetes Research Foundation's (JDRF's) innovative industry discovery and development partnership (IDDP) program, through which JDRF partners with pharmaceutical, biotech, and medical device businesses looking to develop drugs, treatments, technologies, and other therapeutics leading to a cure, reversal, or prevention of type 1 diabetes and its complications.
Through its IDDP program, JDRF will provide up to $3 million toward the Phase I/II clinical trial. Funding will be based on Bayhill attaining specific clinical milestones expected to be reached by the third quarter of 2009.
Mark Schwartz, president and CEO of Bayhill, said: "This agreement demonstrates JDRF's commitment to funding ground-breaking clinical research and to the development of novel therapeutics that can potentially have an important impact on the lives of people with diabetes. There are currently no disease-modifying products available to the millions of patients suffering from this disease. We believe BHT-3021 will provide a better treatment alternative for them."